Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126925681 | 12692568 | 1 | I | 20160815 | 20160829 | 20160829 | EXP | US-CIPLA LTD.-2016US17611 | CIPLA | 0.00 | Y | 0.00000 | 20160829 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126925681 | 12692568 | 1 | PS | VALACYCLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 1 G, BID | U | U | 0 | 1 | G | BID | |||||
| 126925681 | 12692568 | 2 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 3 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 4 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 5 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | 0 | ||||||||||||
| 126925681 | 12692568 | 6 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 7 | SS | Vincristine | VINCRISTINE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 8 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 9 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 10 | SS | Vancomycin | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | UNK | Y | U | 0 | ||||||||
| 126925681 | 12692568 | 11 | SS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | UNK | Y | U | 0 | ||||||||
| 126925681 | 12692568 | 12 | SS | SORAFENIB | SORAFENIB | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 13 | SS | Carmustine | CARMUSTINE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 14 | SS | Carmustine | CARMUSTINE | 1 | 0 | ||||||||||||
| 126925681 | 12692568 | 15 | SS | Melphalan | MELPHALAN | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 16 | SS | Melphalan | MELPHALAN | 1 | 0 | ||||||||||||
| 126925681 | 12692568 | 17 | SS | Everolimus | EVEROLIMUS | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 18 | SS | DAPTOMYCIN. | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | UNK | U | U | 0 | ||||||||
| 126925681 | 12692568 | 19 | SS | CYTARABINE. | CYTARABINE | 1 | Unknown | UNK | 0 | ||||||||||
| 126925681 | 12692568 | 20 | SS | CYTARABINE. | CYTARABINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126925681 | 12692568 | 1 | Oral herpes |
| 126925681 | 12692568 | 2 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 3 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 4 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 5 | Bone marrow conditioning regimen |
| 126925681 | 12692568 | 6 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 7 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 8 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 9 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 10 | Febrile neutropenia |
| 126925681 | 12692568 | 11 | Febrile neutropenia |
| 126925681 | 12692568 | 12 | Disease recurrence |
| 126925681 | 12692568 | 13 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 14 | Bone marrow conditioning regimen |
| 126925681 | 12692568 | 15 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 16 | Bone marrow conditioning regimen |
| 126925681 | 12692568 | 17 | Disease recurrence |
| 126925681 | 12692568 | 18 | Dermatitis bullous |
| 126925681 | 12692568 | 19 | Diffuse large B-cell lymphoma refractory |
| 126925681 | 12692568 | 20 | Bone marrow conditioning regimen |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126925681 | 12692568 | DE |
| 126925681 | 12692568 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126925681 | 12692568 | Acute kidney injury | |
| 126925681 | 12692568 | Disease recurrence | |
| 126925681 | 12692568 | Drug intolerance | |
| 126925681 | 12692568 | Febrile neutropenia | |
| 126925681 | 12692568 | Oral herpes | |
| 126925681 | 12692568 | Palmar-plantar erythrodysaesthesia syndrome | |
| 126925681 | 12692568 | Renal tubular necrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |